AVENUE THERAPEUTICS, INC. Uncategorized Contracts & Agreements
17 Contracts & Agreements
- At the Market Offering Agreement, dated May 10, 2024, by and between Avenue Therapeutics, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on May 13, 2024)
- Form of Investor Inducement Letter (Filed With SEC on May 1, 2024)
- Description of Securities of Avenue Therapeutics, Inc (Filed With SEC on March 18, 2024)
- Form of November 2023 Investor Inducement Letter (Filed With SEC on January 8, 2024)
- Form of January 2023 Investor Inducement Letter (Filed With SEC on January 8, 2024)
- Description of Securities of Avenue Therapeutics, Inc (Filed With SEC on March 31, 2023)
- Placement Agent Agreement entered into by and between the Company and Aegis Capital Corp., dated January 27, 2023 (Filed With SEC on February 1, 2023)
- Form of Lockup Agreement (Filed With SEC on February 1, 2023)
- Description of Securities of Avenue Therapeutics, Inc (Filed With SEC on March 25, 2022)
- Description of Securities (Filed With SEC on March 31, 2021)
- Description of Securities (Filed With SEC on March 30, 2020)
- Form of CVR Agreement (Filed With SEC on February 11, 2019)
- Restrictive Covenant Agreement, dated as of November 12, 2018, by and between Dr. Lucy Lu, M.D. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 14, 2018)
- Restrictive Covenant Agreement, dated as of November 12, 2018, by and between Fortress Biotech, Inc. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 14, 2018)
- Stockholders Agreement, dated as of November 12, 2018, by and between Avenue Therapeutics, Inc., Fortress Biotech, Inc., Dr. Lucy Lu, M.D. and InvaGen Pharmaceuticals Inc (Filed With SEC on November 14, 2018)
- Avenue Therapeutics, Inc. 2 Gansevoort Street, Th Floor, New York, NY 10014 www.avenuetx.com (Filed With SEC on August 15, 2017)
- Amendment 2 to Asset Transfer andLicense Agreement (Filed With SEC on May 22, 2017)
